Strumento inattivo

Altre lingue Endologix, Inc. Nasdaq

Azioni

US29266S1069

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Endologix LLC Appoints Graham Phillips as Chief Operating Officer	18/06
Endologix LLC Announces Online Publication of the One-Year Results of the DETOUR2 Trial in the Journal of Vascular Surgery	13/05
Endologix LLC Appoints Mike Mathias as Chief Commercial Officer	05/03
Endologix LLC Announces That Art Taylor Joins Board of Directors	25/01
Endologix LLC Appoints Scott Ward Joins Board of Directors	09/01
Endologix LLC Announces Appointment of Scott Ward as Board of Directors	09/01
Endologix LLC Announces the U. S. Centers for Medicare & Medicaid Services Grants Transitional Pass-Through Payment for the Detour System	27/12
Endologix Announces Results of Pooled Analysis of DETOUR1 and DETOUR2 Studies at 2023 VIVA Late-Breaking Clinical Trial Session	02/11
Endologix Llc Announces the U. S. Centers for Medicare & Medicaid Services Grants New Technology Add-On Payment for the Detour System	07/09/23
Endologix LLC Appoints Lucas Buchanan to its Board of Directors	24/08/23
Endologix Announces First Patients Treated with the DETOUR?? System, Advancing Treatment for Complex Peripheral Artery Disease	18/07/23
Endologix LLC Announces 24-Month Results of DETOUR-2 Study at 2023 Vascular Annual Meeting	15/06/23
Endologix Llc Receives Fda Approval of the Detour System to Treat Long Complex Superficial Femoropopliteal Lesions in Patients with Pad	08/06/23
Endologix LLC Announces 150Th Patient Enrolled in JAGUAR Randomized Controlled Trial	23/05/23
Endologix Announces 12-Month Results of DETOUR-2 Trial at 2022 VIVA Late-Breaking Clinical Trial Session	11/11/22
Endologix LLC Announced the Five-Year Results from the Leopard Randomized Controlled Trial	03/11/22
Endologix LLC Announces the Elevate	20/10/22
Endologix LLC Submits Premarket Approval Application to FDA for the DETOUR System	10/10/22
Endologix Reports 12 Month Data from DETOUR 2 Clinical Trial at 2022 Vascular Annual Meeting	23/06/22
Endologix Announces Completion of Enrollment in the TORUS 2 Study for PAD in SFA	23/11/21

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Endologix, Inc. Nasdaq

Azioni

US29266S1069

Altre lingue

Filtri